Stephen P Ewald

MEDP General Counsel sold 16,349 shares at $450.00 on 2026-05-28, reducing holdings 44.6% to 20,343 shares; stock now -28.2% from 52-week high.

Stephen P Ewald, General Counsel & Corp. Secy., sold 16,349 shares (16.3K shares) of Medpace Holdings at $450.00, generating $7,357,050.00 ($7.4M) and reducing his non-derivative holdings by 44.6% from 36,692 shares to 20,343 shares. The stock has declined 28.2% from its 52-week high of $628.92 and is currently trading at $451.47, near the transaction price. Ewald's cross-ticker history shows 5 prior sells against only 1 buy across all holdings. The company itself remains fundamentally solid with $706.6M in quarterly revenue, $123.9M net income, and 20.0% annual revenue growth, trading at a P/E of 28.01 with a $12.9B market cap, suggesting the sale reflects a portfolio decision rather than distress. Investors should note the substantial share reduction by a senior officer concurrent with a significant retreat from the stock's recent highs.

General Counsel Ewald sells 15.2K MEDP shares at $598.85 for $9.1M, reducing stake 53.3%

Stephen P. Ewald, General Counsel & Corporate Secretary, executed a substantial sale of 15,230 shares at $598.85 on 2025-10-27, valued at $9,120,485.50, reducing his holdings from 28,573 shares to 13,343 shares—a 53.3% reduction in position size. The sale occurred near the 52-week high of $605.20, just 3.4% below the peak. Ewald's cross-ticker track record shows mixed timing with 4 prior sells averaging +2.7% 30-day and +7.7% 90-day returns at a 50.00% well-timed rate; at MEDP specifically, his prior sales have yielded inconsistent outcomes, with 2 of 5 trades well-timed at the 90-day mark. The stock has rallied +16.7% over the past 30 days and +36.8% over 90 days, suggesting the transaction was executed during strong momentum rather than at a valuation inflection point given the company's healthy 11.8% annual revenue growth and P/E of 38.03.

General Counsel Ewald sells 3,000 MEDP shares at $450.00 for $1,350,000; retains 10,343 shares post-transaction.

Stephen P. Ewald, General Counsel & Corporate Secretary, executed an open-market sale of 3,000 shares at $450.00 on 2025-07-28, reducing his holdings by 22.5% to 10,343 shares. The sale occurred as MEDP traded near recent highs (6.2% below its 52-week peak of $477.73 and sharply elevated on 44.2% 30-day appreciation), providing favorable exit pricing. Ewald's historical cross-ticker sell activity exhibits a 66.67% well-timed rate at the 90-day horizon, and at MEDP specifically, 2 of 4 prior trades were well-timed, suggesting modest pattern consistency; however, his most recent MEDP trade (a buy on 2025-02-27) showed negative 90-day returns of -9.9%, indicating limited predictive power from his recent activity. The company's fundamentals remain solid (11.8% annual revenue growth, $90.3M net income on $603.3M quarterly revenue), though the elevated P/E of 30.08 reflects current valuation strength rather than distress, so the sale appears execution-driven rather than conviction-based.

General Counsel Ewald bought 2 shares of MEDP at $326.11, raising holdings to 13,343 shares.

Stephen P. Ewald, General Counsel & Corporate Secretary, acquired 2 shares on 2025-02-27 at $326.11, a modest transaction that increased his holdings by 0.0% to 13,343 shares. The stock is currently trading at $327.32, down 28.4% from its 52-week high of $457.29, with recent weakness of 4.6% over 30 days and 3.9% over 90 days. His same-ticker history at MEDP shows 3 prior sells with mixed timing outcomes: 2 of 3 were well-timed at the 90-day mark, indicating he has occasionally sold before subsequent declines. This current purchase of 2 shares represents a minimal position adjustment and provides no meaningful signal regarding either confidence or portfolio allocation; the transaction is too small in absolute terms and relative to his 13,343-share base to warrant significant investor attention.